Business Description
Enzymatica AB
ISIN : SE0003943620
Total Employee Number:
19Compare
Compare
Traded in other countries / regions
ENZY.SwedenEN9.Germany IPO Date
2015-06-15Description
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.93 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | -0.33 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 9.93 | |||||
Beneish M-Score | -4.01 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -8.8 | |||||
3-Year EBITDA Growth Rate | 19 | |||||
3-Year EPS without NRI Growth Rate | 19.8 | |||||
3-Year FCF Growth Rate | 25.4 | |||||
3-Year Book Growth Rate | -10.4 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.06 | |||||
9-Day RSI | 22.13 | |||||
14-Day RSI | 28.37 | |||||
3-1 Month Momentum % | -5.3 | |||||
6-1 Month Momentum % | 31.93 | |||||
12-1 Month Momentum % | -7.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.01 | |||||
Quick Ratio | 4.83 | |||||
Cash Ratio | 2.89 | |||||
Days Inventory | 281.32 | |||||
Days Sales Outstanding | 56.82 | |||||
Days Payable | 77.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11 | |||||
Shareholder Yield % | -0.6 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 57.69 | |||||
Operating Margin % | -86.01 | |||||
Net Margin % | -88.3 | |||||
EBITDA Margin % | -81.85 | |||||
FCF Margin % | -58.61 | |||||
OCF Margin % | -58.07 | |||||
ROE % | -37.42 | |||||
ROA % | -32.82 | |||||
ROIC % | -42.58 | |||||
3-Year ROIIC % | -98.83 | |||||
ROC (Joel Greenblatt) % | -134.58 | |||||
ROCE % | -33.25 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 8.63 | |||||
PB Ratio | 4.56 | |||||
Price-to-Tangible-Book | 13.18 | |||||
EV-to-EBIT | -10.21 | |||||
EV-to-Forward-EBIT | 52.14 | |||||
EV-to-EBITDA | -10.56 | |||||
EV-to-Forward-EBITDA | 571.1 | |||||
EV-to-Revenue | 8.65 | |||||
EV-to-Forward-Revenue | 4.81 | |||||
EV-to-FCF | -15.03 | |||||
Price-to-GF-Value | 0.87 | |||||
Price-to-Median-PS-Value | 0.9 | |||||
| Price-to-Net-Current-Asset-Value | 46.13 | |||||
Earnings Yield (Greenblatt) % | -9.8 | |||||
FCF Yield % | -6.8 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Enzymatica AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 51.928 | ||
| EPS (TTM) (kr) | -0.19 | ||
| Beta | -3.5421 | ||
| 3-Year Sharpe Ratio | 0.29 | ||
| 3-Year Sortino Ratio | 0.76 | ||
| Volatility % | 73.53 | ||
| 14-Day RSI | 28.37 | ||
| 14-Day ATR (kr) | 0.1783 | ||
| 20-Day SMA (kr) | 2.2085 | ||
| 12-1 Month Momentum % | -7.75 | ||
| 52-Week Range (kr) | 1.6 - 3.4 | ||
| Shares Outstanding (Mil) | 242.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Enzymatica AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Enzymatica AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-29 | In 92 days | ||
| Second quarter earnings results for 2026 | 2026-07-16 | 2.32 (+1.31%) | ||
| General meeting for 2026 | 2026-05-07 | 2.58 (+1.98%) | ||
| First quarter earnings results for 2026 | 2026-04-28 | 2.67 (-4.64%) | ||
| Annual report for 2025 | 2026-04-14 | 2.95 (-1.67%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-18 | 1.65 (-0.30%) | ||
| Third quarter earnings results for 2025 | 2025-10-30 | 1.96 (+0.77%) | ||
| Second quarter earnings results for 2025 | 2025-07-17 | 2.94 (+0.68%) | ||
| General meeting for 2025 | 2025-05-07 14:30 | 3.00 (-1.64%) | ||
| First quarter earnings results for 2025 | 2025-04-29 | 3.35 (-4.56%) |
Show
Entries
Enzymatica AB Frequently Asked Questions
What is Enzymatica AB(OSTO:ENZY)'s stock price today?
The current price of OSTO:ENZY is kr1.85. The 52 week high of OSTO:ENZY is kr3.40 and 52 week low is kr1.60.
When is next earnings date of Enzymatica AB(OSTO:ENZY)?
The next earnings date of Enzymatica AB(OSTO:ENZY) is 2026-10-29.
Does Enzymatica AB(OSTO:ENZY) pay dividends? If so, how much?
Enzymatica AB(OSTO:ENZY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Enzymatica AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers